Surrozen reports developments as a clinical-stage biotechnology company developing Wnt-based targeted therapeutics for sight-threatening ophthalmic diseases. Company updates center on its ophthalmology pipeline, including SZN-8141 and SZN-8143 in retinal diseases, antibody-engineering work, financial results, collaboration and license revenue, and research milestones tied to Boehringer Ingelheim.
Recurring announcements also cover healthcare investor conference presentations, Nasdaq inducement equity grants under the 2025 Equity Inducement Plan, and corporate governance or leadership matters that affect the company's public-company reporting profile.
Surrozen (Nasdaq: SRZN) announced promising results from recent studies published in Translational Vision Science and Technology. The research highlighted SZN-413, a bi-specific antibody targeting FZD4 and LRP5, as a potential novel treatment for diabetic retinopathy, a major cause of vision loss. SZN-413 was shown to effectively reduce retinal vascular leakage by approximately 80% and significantly diminished areas of pathologic neovascularization. This mechanism may address both retinal non-perfusion and leakage, indicating a potential breakthrough for retinal vascular diseases.
Surrozen, Inc. (SRZN) reported Q2 2022 financial results and provided a corporate update, marking its transition to a clinical stage company. The company has initiated Phase 1 trials for lead candidates SZN-1326, targeting moderate to severe ulcerative colitis, and SZN-043, aimed at severe alcoholic hepatitis. Both candidates have shown promising preclinical results without adverse effects. Additionally, preclinical data on SZN-413 for diabetic retinopathy was presented. The company emphasized ongoing advancements in its Wnt modulation therapies for tissue repair.
Surrozen, Inc. (Nasdaq: SRZN) has initiated a two-part Phase 1 clinical trial for SZN-043, a novel bispecific protein targeting ASGR1, aimed at treating severe alcoholic hepatitis. The trial's first part involves administering single doses to healthy volunteers, with doses ranging from 3 mg to 30 mg. The second part will assess multiple doses in patients with liver cirrhosis. The primary endpoint focuses on safety and tolerability. Preclinical studies indicate SZN-043 may enhance liver function and reduce fibrosis without adverse effects.
Surrozen, Inc. (NASDAQ: SRZN) announced significant advancements in its lead therapeutic programs at Digestive Disease Week 2022. The company's clinical study of SZN-1326 is currently underway, targeting moderate to severe ulcerative colitis, while the SZN-043 study is expected to commence in Q3 2022 for severe alcoholic hepatitis. Presentations highlighted SZN-1326's mechanism in promoting colonic mucosal healing and SZN-043's role in enhancing hepatocyte proliferation. Both candidates showed promising results in preclinical models, demonstrating therapeutic potential without adverse effects.
Surrozen (Nasdaq: SRZN) announced the dosing of the first subject in its three-part Phase 1 clinical trial for SZN-1326, aimed at treating moderate to severe ulcerative colitis. This milestone was achieved a quarter earlier than expected. The trial includes safety and pharmacokinetics evaluations with doses ranging from 25 mg to 1500 mg. SZN-1326, a bi-specific antibody targeting the Wnt pathway, demonstrated strong preclinical results, suggesting potential for tissue repair and anti-inflammatory effects without adverse effects observed in animal studies.
Surrozen (Nasdaq: SRZN) published results indicating that its proprietary Wnt mimetic antibody, SZN-1326, demonstrated significant potential for treating inflammatory bowel disease (IBD). The study, published in Cellular and Molecular Gastroenterology and Hepatology, utilized a mouse model and showed that SZN-1326 effectively repaired injured colon epithelium while sparing healthy tissue. With no current therapies targeting epithelial repair, Surrozen is set to initiate Phase 1 clinical trials for SZN-1326 in Q3 2022, addressing a notable medical need in ulcerative colitis management.
Surrozen, Inc. (Nasdaq: SRZN) announced financial results for Q1 2022 and provided an update on its clinical pipeline. The company is set to initiate Phase 1 clinical trials for its lead product candidates, SZN-1326 targeting moderate to severe ulcerative colitis and SZN-043 for severe alcoholic hepatitis, in Q3 2022. Both candidates demonstrated substantial efficacy in preclinical trials without adverse effects. Surrozen is also advancing SZN-413 for retinal vascular diseases, with promising preclinical data supporting its potential. The firm remains focused on transitioning to a clinical-stage organization.
Surrozen, a biotechnology company focused on the Wnt pathway for tissue repair, announced that CEO Craig Parker will present at the BofA Securities 2022 Healthcare Conference on May 11 at 4 p.m. PT. The event will be available via a live audio webcast on Surrozen's Investor Relations website, with an archived version accessible later. Surrozen is developing targeted drug candidates for conditions such as inflammatory bowel disease and hearing loss, among others. For more details, visit Surrozen's official website.
Surrozen (Nasdaq: SRZN) announced promising preclinical data for its novel SZN-413, which targets retinal vascular diseases like diabetic retinopathy. Presented at the ARVO Annual Meeting, the data shows SZN-413 significantly reduced pathological neovascular tuft formation and avascular area in mouse models. Additionally, it demonstrated an ~80% reduction in retinal vascular leakage in rabbit models. This progress suggests a new therapeutic strategy in addressing retinal issues caused by diabetes, highlighting the potential of Wnt signaling in regenerative therapies.
Surrozen, Inc. (Nasdaq: SRZN) is advancing its lead therapeutic candidates, SZN-1326 and SZN-043, aimed at treating moderate to severe ulcerative colitis and severe alcoholic hepatitis, respectively. The company expects to initiate Phase 1 clinical trials in healthy volunteers by Q3 2022. SZN-1326 has shown promise in preclinical models for intestinal regeneration, while SZN-043 targets liver function improvement. Additionally, Surrozen continues to broaden its therapeutic pipeline with new candidates targeting vascular-associated retinopathies and potential therapies for dry eye and lung diseases.